证券代码：300119 证券简称：瑞普生物 公告编号：2025-088 瑞普生物股份有限公司 关于设立及变更募集资金专户并授权签署三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 10 月 24 日召开第五届董事会第二十九次（临时）会议及第五届监事会第二十五次 （临时）会议，审议通过了《关于设立及变更募集资金专户并授权签署三方监管 协议的议案》，同意根据 2021 年向特定对象发行股票部分募集资金投资项目变 更需求，在渤海银行开立新的募集资金专项账户，并变更原在平安银行（账号： 15535008370073）、中国建设银行（账号：12050162660100002432）开立的募集 资金专户用途为"生物制造产业化工程建设项目"。董事会授权董事长及董事长 授权的人员办理开立及变更募集资金专项账户相关事宜，包括但不限于开立募集 资金专项账户、签署募集资金专户存储三方监管协议等。 现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2021 年 9 月 10 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-085 瑞普生物股份有限公司 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2、审议通过了《关于设立及变更募集资金专户并授权签署三方监管协议的 议案》 第五届监事会第二十五次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届监事会第二十五次（临 时）会议于 2025 年 10 月 24 日在公司会议室以现场表决方式召开。会议通知于 2025 年 10 月 21 日以书面及电子邮件等方式送达全体监事。公司应出席监事 3 人，实际出席监事 3 人，参与表决监事 3 人。本次会议由监事会主席周仲华先生 主持。本次会议的召集、召开和表决程序符合《公司法》《证券法》等法律法规 和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于 2025 年第三季度报告的议案》 经审议，监事会认为公司《2025 年第三季度报告》编制及审议程序符合法 律、行政法规和中国证监会等相关规定，报告内容真实、准确、完整地 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届董事会第二十九次（临 时）会议于 2025 年 10 月 24 日在公司会议室以现场结合通讯表决方式召开。会 议通知于 2025 年 10 月 21 日以书面及电子邮件等方式送达全体董事。公司应出 席董事 9 人，实际出席董事 9 人（其中：董事刘爱玲、李睿、杨鶄，独立董事郭 春林、才学鹏、李娅以通讯方式参会），参与表决董事 9 人。本次会议由董事长 李守军先生主持，公司高级管理人员列席了会议。本次会议的召集、召开和表决 程序符合《公司法》《证券法》等法律法规和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于 2025 年第三季度报告的议案》 经审议，董事会认为《2025 年第三季度报告》编制和审核的程序符合法律、 行政法规和中国证监会等相关规定，报告内容真实、准确、完整地反映了公司 2025 年三季度的经营状况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司董事、监事、高级管理人员对该报告签署了书面确认意见。 具体内容详 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥836,737,374.53, representing a year-on-year increase of 1.44%[5] - Net profit attributable to shareholders for Q3 2025 was ¥105,784,584.02, up 23.02% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥81,536,762.58, reflecting a 7.64% increase year-on-year[5] - For the first nine months of 2025, the company achieved a total revenue of ¥2,544,325,031.33, a 13.50% increase from the previous year[9] - The net profit attributable to shareholders for the first nine months was ¥362,307,052.90, which is a 45.64% increase year-on-year[9] - Operating profit for the current period was ¥442,271,734.21, up 39.6% from ¥316,434,076.01 in the previous period[27] - Net profit attributable to shareholders of the parent company was ¥362,307,052.90, representing a 45.6% increase from ¥248,766,437.96 in the previous period[28] - Earnings per share (EPS) for the current period was ¥0.7972, up from ¥0.5401 in the previous period[28] Cash Flow and Assets - The company's cash flow from operating activities for the first nine months was ¥205,880,305.22, down 45.46% compared to the previous year[11] - The company's short-term borrowings decreased to 736.81 million yuan from 800.78 million yuan[25] - Accounts payable decreased to 320.68 million yuan from 362.87 million yuan[25] - The company reported a net cash flow from operating activities of ¥205,880,305.22, down 45.4% from ¥377,458,172.51 in the previous period[30] - The company generated cash inflows from investment activities totaling ¥2,254,967,689.98, a decrease from ¥2,604,449,087.07 in the previous period[30] - Cash and cash equivalents at the end of the period increased to $486.83 million, up from $350.51 million, representing a growth of approximately 39%[31] - The company’s cash flow from investment activities showed a net inflow of $60.29 million, a turnaround from a net outflow of -$269.18 million previously[31] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥7,690,888,248.95, a decrease of 3.45% from the end of the previous year[5] - Total liabilities decreased to ¥2,540,845,487.30 from ¥2,958,832,996.02, a reduction of 14.1%[26] - Total equity increased to ¥5,150,042,761.65 from ¥5,006,960,057.85, reflecting a growth of 2.8%[26] - Current assets totaled 3.61 billion yuan, a decrease from 3.65 billion yuan at the start of the period[24] - The company's non-current assets totaled 4.08 billion yuan, down from 4.32 billion yuan at the beginning of the period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,144[13] - The largest shareholder, Li Shoujun, holds 36.04% of shares, totaling 167,474,479 shares, with 125,605,859 shares pledged[13] - The second-largest shareholder, Liang Wu, holds 5.04% of shares, totaling 23,405,578 shares, with 11,730,000 shares pledged[13] - The total number of restricted shares at the beginning of the period was 130,866,730, with 1,093,425 shares released and 19,380 shares added, resulting in 129,792,685 restricted shares at the end of the period[17] - The company has a high concentration of ownership, with the top five shareholders holding over 50% of the total shares[13] - The company has not reported any changes in the number of preferred shareholders or their holdings[15] Research and Development - Research and development expenses rose to ¥157,025,388.67, an increase of 16.2% compared to ¥135,162,744.28 in the previous period[27] - The company received clinical trial approval for the world's first mRNA vaccine for food animals, enhancing its product line and industry reputation[18] - In Q3, the company obtained approvals for 7 new veterinary products, including vaccines and antibiotics, to strengthen its product matrix in the pet and livestock medicine sectors[18] Investments and Projects - The company has changed part of its fundraising purpose to invest 296 million yuan in a microbial protein industrialization project, with a total investment of 679 million yuan[20] - A joint venture was established with Shengwei Biotechnology to develop vaccines for ruminants, with the company investing 27 million yuan for a 43.55% stake[22] Other Financial Information - The company completed the cancellation of 1,093,200 restricted stock units, reducing its registered capital from 465,847,906 yuan to 464,754,706 yuan[21] - The impact of exchange rate changes on cash and cash equivalents was a positive $196,030.85, down from $392,159.94, reflecting a decrease of approximately 50%[31] - The third quarter financial report was not audited, which may affect the reliability of the reported figures[32]

Core Insights - The company reported third-quarter revenue of 837 million yuan, representing a year-on-year increase of 1.44% [1] - The net profit for the third quarter was 106 million yuan, showing a year-on-year growth of 23.02% [1] - For the first three quarters, the total revenue reached 2.544 billion yuan, marking a year-on-year increase of 13.50% [1] - The net profit for the first three quarters was 362 million yuan, reflecting a significant year-on-year growth of 45.64% [1]

Core Viewpoint - The animal health sector experienced a slight increase of 0.21% on October 24, with significant contributions from specific stocks, particularly Biological Shares, which led the gains [1] Market Performance - The Shanghai Composite Index closed at 3950.31, up 0.71% - The Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance in Animal Health Sector - Biological Shares (600201) closed at 10.77, up 2.87% with a trading volume of 311,900 shares and a turnover of 333 million yuan - Other notable stocks include: - *ST Green Health (002868): closed at 29.09, up 0.66% - Shunlian Biological (688098): closed at 10.75, up 0.66% - Huisheng Biological (300871): closed at 20.75, up 0.48% - Yongshun Biological (920729): closed at 9.68, up 0.31% - Jinhe Biological (002688): closed at 6.68, unchanged [1] Capital Flow Analysis - The animal health sector saw a net inflow of 8.6031 million yuan from institutional investors, while retail investors experienced a net outflow of 24.4195 million yuan [2] - The breakdown of capital flow indicates: - Repu Biological (300119) had a net inflow of 9.2707 million yuan from institutional investors - Biological Shares (600201) saw a net inflow of 8.4244 million yuan - Kexin Biological (688526) had a net inflow of 5.4428 million yuan from institutional investors [3]

Group 1 - The core point of the article is that Reap Bio (300119) has indicated that as of October 20, 2025, the total number of shareholders is expected to be approximately 25,000 [1]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.02% on October 21, with Bioworks leading the drop. Meanwhile, the Shanghai Composite Index rose by 1.36% and the Shenzhen Component Index increased by 2.06% [1]. Group 1: Market Performance - The animal health sector's performance was mixed, with individual stocks showing varying degrees of increase and decrease. Notably, the top gainers included: - Driving Force (4.50% increase) [1] - Dayu Biological (3.46% increase) [1] - Yongshun Biological (2.06% increase) [1] - Conversely, Bioworks saw a decline of 2.10%, leading the losses in the sector [2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector indicated a net outflow of 151 million yuan from institutional investors, while retail investors saw a net inflow of 116 million yuan [2]. - The capital flow for individual stocks showed significant movements, with: - Key stock, Bioworks, experiencing a net outflow of 6.46 million yuan from institutional investors [3]. - Retail investors contributed a net inflow of 7.59 million yuan to Zhongmu Co. [3]. Group 3: Individual Stock Analysis - The following stocks had notable capital flows: - KQ Biological had a net inflow of 1.83 million yuan from institutional investors [3]. - ST Green Health faced a net outflow of 4.37 million yuan from institutional investors [3]. - The stock of Rui Pu Biological saw a net inflow of 17.22 million yuan from retail investors despite a net outflow from institutional investors [3].

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [9][62]. Core Views - The swine sector is undergoing deepening regulation, with a focus on value reassessment opportunities. The report suggests that the price of pigs may face downward pressure in the short term due to increased market supply, but regulatory measures are expected to stabilize prices in the long run [1][16]. - The poultry sector is anticipated to improve, with data indicating a rise in the number of breeding stock and a shift towards self-breeding [2][27]. - The animal health sector is seeing a potential improvement in competitive dynamics, particularly with the progress of clinical trials for African swine fever vaccines, which could enhance market conditions [3][35]. - The pet economy is thriving, with domestic brands gaining strength and the market expected to continue its rapid growth [9][55]. Summary by Sections Swine - The swine industry is in a regulatory phase aimed at controlling prices through capacity reduction. The average price of pigs is reported at 11.02 yuan/kg, with a weekly decrease of 0.87 yuan/kg. The number of breeding sows is stable at 40.38 million heads [15][16]. - Recommended companies include Muyuan Foods and Wens Foodstuffs, with additional attention on Dekang Agriculture, Shennong Group, and Juxing Agriculture [1][16]. Poultry - The poultry sector shows signs of improvement, with a total of 80.33 thousand sets of breeding stock updated in the first three quarters of 2025. The report highlights a shift towards self-breeding, with self-bred stock accounting for 59% [2][27]. - Recommended companies in this sector are Shennong Development and Lihua Stock [2][27]. Animal Health - The competitive landscape in the animal health sector is expected to improve, supported by government initiatives to optimize the veterinary drug industry. The report notes that clinical trials for African swine fever vaccines are underway, which could lead to commercialization [3][35]. - Recommended companies include Kexin Biological and Ruipu Biological, with additional focus on Huisheng Biological, Zhongmu Biological, and others [3][35]. Planting - The report indicates a declining pig-to-grain price ratio, with the current ratio at 4.95. The prices of corn and soybean meal have shown slight fluctuations, with corn priced at 2181 yuan/ton [39][44]. - Companies to watch include Suqian Agricultural Development, Longping High-Tech, and Denghai Seeds [7][44]. Feed - Feed prices are experiencing fluctuations, with the price for fattening pig feed at 3.34 yuan/kg. The report notes a year-on-year increase in industrial feed production [45][46]. - Recommended companies include Haida Group and He Feng Shares [45][46]. Pets - The pet market is projected to reach 300.2 billion yuan in 2024, with a year-on-year growth of 7.5%. The report highlights the increasing consumption per pet, with dogs averaging 2961 yuan and cats 2020 yuan annually [55][56]. - Recommended companies in the pet food sector include Guibao Pet, Zhongchong Shares, and Petty Shares, with Ruipu Biological in the pet medical sector [9][55].